Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about buprenorphine treatment for adolescents and young adults from this journal article from The Journal of Addiction Medicine 2018.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about adolescent buprenorphine overdosing from this journal article from The Journal of Addiction Medicine 2018. Jacob T. Borodovsky, BA

    Learning objectives: 

    1. Understand the limits of current scientific knowledge concerning best practices for treating adolescents and young adults with opioid use disorder.
    2. Learn clinically-relevant characteristics of adolescents and young adults with opioid use disorder.
    3. Gain insight into the evidence-based components of buprenorphine treatment programs and protocols that optimize treatment outcomes for adolescents and young adults with opioid use disorder.


  • The Nicotine Content of a Sample of E-cigarette Liquid Manufactured in the United States (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about nicotine content within e-cigarettes from this journal article from The Journal of Addiction Medicine 2018.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about nicotine content within e-cigarettes from this journal article from The Journal of Addiction Medicine 2018. Katreena Collette-Merrill PhD, RN

    Learning objectives: 

    1. Recognize the potential health concerns with e-cigarette use

    2. Understand the discrepancy between labelled vs. measured e-liquid concentrations

    3. List the impact of mislabeling e-liquid on those who use e-cigarettes


  • Does Maternal Buprenorphine Dose Affect Severity or Incidence of Neonatal Abstinence Syndrome? (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about maternal buprenorphine doses from this journal article from The Journal of Addiction Medicine 2018.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about maternal buprenorphine dose from this journal article from The Journal of Addiction Medicine 2018. Jaqueline Wong, MD

    Learning objectives: 

    1. Describe the study population, including maternal buprenorphine doses
    2. Describe study exclusions, including maternal urine drug screen results
    3. Describe which factors predict the need for morphine treatment of neonatal abstinence syndrome and which do not based on the article's findings



  • The ASAM State of the Art Course in Addiction Medicine 2018 (19 CME)

    Product not yet rated Contains 12 Product(s)

    Earn up to 19 CME using this on-demand package of courses, containing the conference recordings, resources, practice questions, and slides from The ASAM State of the Art Course in Addiction Medicine, 2018. The ASAM State of the Art Course in Addiction Medicine presents dynamic and cutting-edge breakthroughs in the addiction medicine field.

    image

    Overview

    This course is designed specifically for physicians and healthcare professionals seeking an advanced level of knowledge about breakthroughs in the field and will include:

    • Presentations focused on scientific advances and emerging evidence in addiction medicine
    • Sessions organized around ten topics that translate into clinically useful knowledge
    • Special addresses by directors of federal agencies including SAMHSA, NIDA, NIAAA
    • Concise presentations delving into understanding, preventing, diagnosing and treating addiction and co-occurring medical and psychiatric disorders

    Learning Objectives

    Upon completion, participants should be able to:

    1. Identify the latest epidemiology and prescribing guidelines for opioids and treatment approaches for opioid use disorder.
    2. Identify the latest trends in marijuana legislation, policy, testing, synthetic cannabinoids, and implications for practice.
    3. Explain how animal models are being used to develop medications for stimulant use disorders.
    4. Describe the implications of excessive alcohol use in adolescents, young adults, and women of child bearing potential.
    5. Apply suicide screening and interventions to reduce selfharm in substance-dependent populations.
    6. Refer to behavioral therapies and understand how they are being integrated into new technologies.

    Target Audience

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who seek an advanced level of knowledge of addiction medicine
    • Primary care clinicians who manage patients with addiction in their practice
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine



    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The ASAM CME Committee and Reviewers Disclosure Listing

    First Name Commercial Interests Compensation Received For what Role?
    Timothy Brennan MD, MPH, FASAM None
    Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance
    Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs 
    James Finch MD, DFASAM None

    Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board
    David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
    Adam Gordon, MD, MPH None
    Leslie Hayes, MD None
    Abigail Herron DO, DFASAM None
    Petros Levounis MD, MA, FASAM None
    Carla Marienfeld MD None
    Ricardo Restrepo MD, MPH, FASAM None
    Richard Ries MD, DFASAM None
    Edwin Salsitz MD, DFASAM None
    Sharon Stancliff MD, FASAM None
    Timothy Wiegand MD, FACMT, FAACT None
    Erin Zerbo, MD None
    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 20.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 20.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 20.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Session 3: Implications of Expanded Cannabis Access (2 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 2 AMA PRA Category 1 Credit(s)™ while learning more about the implications of expanded access to cannabis, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 3 examines several topics in the field of cannabinoids and cannabis access. This will involve presentations on the epidemiology of cannabis use and cannabis use disorder, followed by an update on cannabis decriminalization, legalization, and use of “medical marijuana” and current laws. Then we will dive into routes of administration, detailed information on “synthetic marijuana,” and the use and consequences thereof. The presentations will describe the consequences of expanded marijuana access in terms of adolescent use, traffic accidents, and marijuana testing in the workplace in states with and without legalization as emerging issues.

    Deborah S. Hasin, PhD, D. Faye Caldwell, JD, Ryan G. Vandrey, PhD, and Michael H. Baumann, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following:  Epidemiology of Cannabis Use and Cannabis Use Disorder, Reefer Madness? Update on Cannabis Laws and "Medical Marijuana", Routes of Marijuana Administration and Testing, and Biological Effects of Synthetic Cannabinoid Drugs Found in the Street Drug Marketplace.

  • Session 8: What’s New in Non-Pharmacological Treatments (1.5 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning more about what is new in non-pharmacological treatments, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 8 will provide a brief description of three commonly utilized non-pharmacologic treatments for addictions: contingency management, 12-Step and technology-enhanced treatment. For all three interventions, data concerning efficacy, predictors of treatment success, and implementation issues will be presented. New research findings will be discussed. Richard K. Ries, MD, FAPA, DFASAM, Lisa A. Marsch, PhD, and Maxine Stitzer, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following: Twelve-Step Facilitation for Those in Treatment for Opioid Use Disorder, Digital Technology-Enhanced Approaches to Treatment and Contingency Management in Clinical Practice.

  • Session 10: Approaches to Treatment of Methamphetamine Use Disorder (2 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 2 AMA PRA Category 1 Credit(s)™ while learning more about approaches to treatment of methamphetamine use disorder, from this conference recording from The ASAM State of the Art Conference, 2018.

    In Session 10, you will learn that methamphetamine use has resurged recently, increasing the need for effective treatment. Behavioral and pharmacological approaches to treatment have been assessed by preclinical and clinical researchers. This session will point out promising preclinical candidates, clinical trials with bupropion and naltrexone, and behavioral therapies with known efficacy. Jane B. Acri, PhD, Richard A. Rawson, PhD, and Frank J. Vocci, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following: Compounds and Mechanisms Evaluated Preclinically as Potential Therapeutics for Methamphetamine Disorders, Behavioral/Psychosocial Treatments for Methamphetamine Dependence: Recent Advances and Medication Development for Treatment of Methamphetamine Use Disorder.

  • Session 2: Cocaine: How the Cellular Basis of its Impact Tells the Story (2 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 2 AMA PRA Category 1 Credit(s)™ while learning more about cocaine and how the cellular basis of its impact tells the story, from this conference recording from The ASAM State of the Art Conference, 2018.

    In session 2, you will learn that cocaine is not just for the 80’s stock broker anymore! The subcellular pharmacokinetics make this a particularly difficult substance to treat. We will walk through the advanced neuroscience, the animal models that define our predictive understanding, and the behavioral aspects of both the pathology and treatment. While opioids have captured recent headlines, cocaine and its close cousin methamphetamine have been smoldering in the background. Although we do not have medications with good evidence for treatment, we can predict the withdrawal syndrome and the behaviors that drive utilization. With this knowledge we can build better interventions that are both helpful and reimbursed. 
  • Session 5: Breaking Down Barriers that Block Quality Care (2.25 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 2.25 AMA PRA Category 1 Credit(s)™ while learning more about breaking down barriers that block quality care, from this conference recording from The ASAM State of the Art Conference, 2018.

    In Session 5, you will wonder why you are even watching this session. I mean, we have access to treatment on demand, everyone knows the evidence, there is ample funding for treatment, and thank goodness that everyone screens for addiction in their practice. Maybe we would need this session if there was stigma, but everyone agrees that addiction is a chronic brain disorder and are competing for treatment centers to open in their neighborhoods. Really, thank goodness that medical schools and residency programs spend a lot of time training new physicians for the complexity of this disease and how to treat it. Because of this, we have a vibrant, motivated workforce just waiting for the next addiction patient. So, I am not sure what we are going to discuss, but it would be great if we had an audience for our speakers. Anthony Campbell, RPH, DO, CDR, USPHS, R. Corey Waller, MD, MS, FACEP, DFASAM, and Chideha M. Ohouha MD, MPHbring their years of experience and expertise to deliver an exceptional presentation covering the following: The Federal Policy Response to Removing Barriers, If Getting into the US Was Like Getting into Addiction Treatment We Wouldn't Need a Wall, Buprenorphine Prescribing: Getting to Yes, and Audience Discussion with Panelists.

  • Session 9: Overdose, Self-Harm, Suicide, and the Gray Areas in Between (1.5 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning more about overdose, self-harm, suicide, and other gray areas in between, from this conference recording from The ASAM State of the Art Conference, 2018.

    During Session 9 you will learn that suicides and fatal drug overdoses are increasing in the US. Moreover, deaths involving drug intoxication are likely underreported, suggesting the problem is worse than the current statistics show. The contribution of the current opioid epidemic to the escalating deaths from overdose will be highlighted and opioid-specific prevention strategies will be discussed. The continuum of self-harm will be considered from both a risk factor and developmental point of view. Assessment of suicide risk and potential intervention strategies to de-escalate risk will be explored. Richard K. Ries, MD, FAPA, DFASAM, Hilary S. Connery, MD, PhD, and Richard K. Ries, MD, FAPA, DFASAMbring their years of experience and expertise to deliver an exceptional presentation covering the following: Overdose Suicide and the Gray Areas in Between, Diagnosis Prevalence and Interventions of Self-Harm in Addiction Patient Populations, and Suicide Screening and Intervention in Individuals with Substance Use Disorders..